

**Rabeprazole (Pariet<sup>®</sup>)**

**No. 118/04**

**Janssen-Cilag**

*Extension of current license to allow for on-demand therapy in the symptomatic treatment of moderate to very severe gastro-oesophageal reflux disease (symptomatic GORD) after resolution of symptoms in patients without oesophagitis.*

**Summary of Recommendation**

13 September 2004

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

**Advice:** following a full submission.

Rabeprazole is accepted for use within NHS Scotland for on-demand symptomatic treatment of moderate to severe gastro-oesophageal reflux disease (GORD) in patients without oesophagitis.

It is the second proton-pump inhibitor (PPI) with a specific licence for on-demand therapy. Provided that there is a clearly defined need for maintenance therapy following acute treatment of GORD and that rabeprazole is considered to be the most appropriate PPI, on-demand use of rabeprazole is an effective treatment option in patients without oesophagitis.

Professor David H Lawson  
Chairman